Lexaria Bioscience (LEXX) EBT Margin (2017 - 2026)

Lexaria Bioscience has disclosed EBT Margin across 10 years of filings, most recently posting 7250.67% for Q1 2026.

• EBT Margin for Q1 2026 came in at 7250.67%, down 566963.0% year-over-year; the trailing twelve-month figure through Feb 2026 was 2570.59% (down 78692.0% YoY), and the FY2025 annual result was 1682.58%, down 44651.0% from the prior year.
• EBT Margin came in at 7250.67% for Q1 2026 at Lexaria Bioscience, down from 1543.55% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 460.69% in Q1 2024 to a low of 7250.67% in Q1 2026.
• The 5-year median for EBT Margin is 2115.1% (2024), against an average of 2663.89%.
• Across the five-year window, EBT Margin jumped 1269960 bps in 2022 and plunged 566963 bps in 2026, its largest moves.
• Lexaria Bioscience's EBT Margin stood at 1734.71% in 2022, then surged by 57 bps to 748.17% in 2023, then slumped by 96 bps to 1462.95% in 2024, then slipped by 6 bps to 1543.55% in 2025, then tumbled by 370 bps to 7250.67% in 2026.
• The last three EBT Margin figures came in at 7250.67% (Q1 2026), 1543.55% (Q3 2025), and 2155.31% (Q2 2025), per Business Quant data.